Cargando…

The Experience of a Multidisciplinary Clinic in the Management of Early-Stage Breast Cancer Patients Receiving Trastuzumab Therapy: An Observational Study

Background. We established a dedicated cardiac oncology clinic in 2008 for the rapid diagnosis and treatment of cardiotoxicity related to cancer therapy. In this retrospective observational study, we report on clinical outcomes in women with early-stage breast cancer (EBC) referred to this clinic. M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dent, Susan, Hopkins, Sean, Graham, Nadine, Johnson, Christopher, Law, Angeline, Campbell, Michelle, Crawley, Freya, Allen, Kathleen, Turek, Michele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3463163/ https://www.ncbi.nlm.nih.gov/pubmed/23050193 http://dx.doi.org/10.1155/2012/135819

Ejemplares similares

Clinical Experience of Patients Referred to a Multidisciplinary Cardiac Oncology Clinic: An Observational Study
por: Sulpher, Jeffrey, et al.
Publicado: (2015)

An International Survey of Health Care Providers Involved in the Management of Cancer Patients Exposed to Cardiotoxic Therapy
por: Sulpher, Jeffrey, et al.
Publicado: (2015)

Diastolic dysfunction can precede systolic dysfunction on MUGA in cancer patients receiving trastuzumab-based therapy
por: Klein, Ran, et al.
Publicado: (2019)

Reporting of coronary artery calcification on chest CT studies in breast cancer patients at high risk of cancer therapy related cardiac events
por: Phillips, William J., et al.
Publicado: (2018)

Cardiac Monitoring and Heart Failure in Advanced Breast Cancer Patients Treated With Trastuzumab in Ontario, Canada
por: Rushton, Moira, et al.
Publicado: (2022)

Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group
por: Mackey, J.R., et al.
Publicado: (2008)

Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel
por: Chiu, Joanne Wing Yan, et al.
Publicado: (2023)

Acute Cardiogenic Shock Induced by Infusional 5-Fluorouracil
por: Sulpher, Jeffrey, et al.
Publicado: (2014)

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
por: Dogan, Izzet, et al.
Publicado: (2023)

A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer
por: Dent, Susan, et al.
Publicado: (2021)

Trastuzumab in the management of early and advanced stage breast cancer
por: Bartsch, Rupert, et al.
Publicado: (2007)

Right heart function deteriorates in breast cancer patients undergoing anthracycline-based chemotherapy
por: Boczar, Kevin Emery, et al.
Publicado: (2016)

The evaluation of left ventricular function for patients being considered for, or receiving Trastuzumab (Herceptin) therapy
por: Fox, K F
Publicado: (2006)

Long-term tolerance and cardiac function in breast cancer patients receiving trastuzumab therapy
por: Huang, Ping, et al.
Publicado: (2016)

Baseline cardiac function checkup in patients with gastric or breast cancer receiving trastuzumab or anthracyclines
por: Ishii, Taisuke, et al.
Publicado: (2022)

Infused Therapy and Survival in Older Patients Diagnosed with Metastatic Breast Cancer who Received Trastuzumab
por: Griffiths, Robert I, et al.
Publicado: (2011)

BSE and BCOS Guideline for Transthoracic Echocardiographic Assessment of Adult Cancer Patients Receiving Anthracyclines and/or Trastuzumab
por: Dobson, Rebecca, et al.
Publicado: (2021)

Comparison of survival outcomes according of patients with metastatic gastric cancer receiving trastuzumab with systemic chemotherapy
por: Ha, Gi-Young, et al.
Publicado: (2020)

Cost of Illness for Patients with Arthritis Receiving Multidisciplinary Rehabilitation Care
por: Grotle, Margreth, et al.
Publicado: (2011)

Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study
por: Blondeaux, Eva, et al.
Publicado: (2020)

Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer
por: McLaughlin, Shannon, et al.
Publicado: (2023)

Resistance to Trastuzumab
por: Vivekanandhan, Sneha, et al.
Publicado: (2022)

Trastuzumab-induced thrombocytopenia after eight cycles of trastuzumab treatment
por: Zhou, Qiong, et al.
Publicado: (2020)

Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
por: Waller, Cornelius F., et al.
Publicado: (2021)

The influence of steroid receptor status on the cardiotoxicity risk in HER2-positive breast cancer patients receiving trastuzumab
por: Huszno, Joanna, et al.
Publicado: (2015)

Real-World Data on Health-Related Quality of Life Assessment in Patients With Breast Cancer Receiving Subcutaneous Trastuzumab
por: Syrios, John, et al.
Publicado: (2018)

Trastuzumab Blocks the Receiver Function of HER2 Leading to the Population Shifts of HER2-Containing Homodimers and Heterodimers
por: Zhao, Jun, et al.
Publicado: (2021)

Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial
por: Barroso-Sousa, Romualdo, et al.
Publicado: (2022)

Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006–2014)
por: Daniels, Benjamin, et al.
Publicado: (2018)

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer
por: Moreno-Aspitia, Alvaro, et al.
Publicado: (2013)

Immune Effects of Trastuzumab
por: Nuti, Marianna, et al.
Publicado: (2011)

Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit
por: Triulzi, Tiziana, et al.
Publicado: (2018)

Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT)
por: Sella, Tal, et al.
Publicado: (2022)

Effect of Central Nervous System Metastases on Treatment Discontinuation and Survival in Older Women Receiving Trastuzumab for Metastatic Breast Cancer
por: Danese, Mark D., et al.
Publicado: (2012)

Risk Profiling of Cancer Treatment-Related Cardiovascular Disorders in Breast Cancer Patients Who Received Adjuvant Chemotherapy With Trastuzumab
por: Shinano, Hiromi, et al.
Publicado: (2020)

An Exploration of Heart Failure Risk in Breast Cancer Patients Receiving Anthracyclines with or without Trastuzumab in Thailand: A Retrospective Study
por: Yoodee, Jukapun, et al.
Publicado: (2021)

Interventions for Preventing Cardiotoxicity in Breast Cancer Patients Receiving Trastuzumab: A Systemic Review and Bayesian Network Meta-Analysis
por: Li, Xinyi, et al.
Publicado: (2021)

Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab
por: Ferraro, Emanuela, et al.
Publicado: (2022)

Cardiac toxic effect of radiation therapy in patients receiving adjuvant trastuzumab treatment, as examined by LVEF of echocardiography: an experimental research
por: Khandoozi, Reza, et al.
Publicado: (2023)

Cardiac function in women receiving dual anti-Her2 antibodies (trastuzumab and pertuzumab) combined with chemotherapy for breast cancer
por: Zekri, Jamal, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rv5dgj26800o6fa8k43oqtjh9k